Linked Life Data

10198757

Source:http://linkedlifedata.com/resource/pubmed/id/10198757

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1999-4-30
pubmed:abstractText
The main components of bromantan central neurotropic effect is its dopamine-positive activity: antagonism (5 mg/kg) to the effects of neuroleptics in rats, blocking (50 microM) of dopamine synaptosomal capture, and a complicated in structure influence on the serotoninergic mediator systems--inhibition of neuronal capture of serotonin (50 microM), behavior responses to 5-hydroxytryptophan (1-20 mg/kg) in mice, decrease in the mediator content in intact rat brain when administered in doses lower than 5 mg/kg, and the absence of this parameter with the use of higher doses. The central noradrenergic effect of the drug is less expressed: blocking of the synaptosomal capture of norepinephrine in higher (more than 500 microM) concentrations), and absence of an effect, in distinction from sydnocarb, 1-5 mg/kg, on the mediator content in intact rat brain. The drug (1-50 mg/kg, intravenously) has no effect on neuro-muscular transmission in cats and in higher doses (30-600 mg/kg) inhibits to a certain degree the central effects of nicotine and arecoline.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0869-2092
pubmed:author
pubmed:issnType
Print
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
11-4
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
[The mechanisms of the neurotropic action of bromantan].
pubmed:affiliation
Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
pubmed:publicationType
Journal Article, English Abstract